Oppenheimer analyst Jay Olson believes the 14% pullback in Portola Pharmaceuticals since the company disclosed on December 22 a three-month delay to the AndexXa FDA action date presents a buying opportunity. The decline is unwarranted as Portola plans to launch two new drugs in 2018, each with sales potential exceeding $1B at peak, Olson tells investors in a research note titled "Stop the Bleeding! Overreaction to AndexXa Delay Creates Buying Opportunity." The analyst sees the three-month delay to AndexXa as "essentially immaterial" to his outlook for the company. Olson reiterates an Outperform rating on Portola Pharmaceuticals with an $80 price target. The stock closed yesterday down 57c to $47.25.